12:00 AM
 | 
Feb 14, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ozurdex dexamethasone intravitreal implant regulatory update

The U.K.'s NICE issued a preliminary appraisal recommending against Ozurdex dexamethasone intravitreal implant from Allergan to treat macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) - its approved indication. The agency requested additional information on the clinical and cost-effectiveness...

Read the full 202 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >